25 Antibody

What is the difference between IL-17E/IL-25 antibody and anti-CD25 antibody?

IL-17E/IL-25 antibodies target the IL-17E cytokine (also known as IL-25), which is involved in inflammatory responses. These antibodies can function as detection reagents in assays or as neutralizing antibodies in functional studies. For example, Human IL-17E/IL-25 antibody (AF1258) functions as an ELISA detection antibody when paired with Mouse Anti-Human IL-17E/IL-25 Monoclonal Antibody .

In contrast, CD25 antibodies target the alpha chain of the IL-2 receptor, which is highly expressed on regulatory T cells (Tregs) and activated T cells. These antibodies can be designed either to block IL-2 signaling or to deplete Tregs while preserving IL-2 signaling pathways in effector T cells .

Methodologically, researchers should carefully select the appropriate antibody based on their experimental needs:

• For cytokine detection: IL-17E/IL-25 antibodies in ELISA systems

• For immune cell modulation: CD25 antibodies for Treg depletion or IL-2 pathway studies

How should I validate IL-25 or CD25 antibodies for my research?

Antibody validation is critically important as "not all companies comply with the highest standards, and thus many reagents fail basic validation tests" . Follow this stepwise validation approach:

• Target binding confirmation:

  • For IL-25 antibodies: Test binding to recombinant IL-25 protein

  • For CD25 antibodies: Verify binding to CD25+ cells (e.g., activated T cells)

• Specificity testing:

  • Cross-reactivity assessments with related molecules

  • Negative controls (samples known to lack the target)

• Functional validation:

  • For IL-25 neutralizing antibodies: Measure inhibition of CXCL1/GRO alpha secretion in HT-29 cells

  • For CD25 antibodies: Assess impact on IL-2 signaling and/or Treg depletion

• Technical validation for specific applications:

  • For flow cytometry: Optimize concentrations and staining protocols

  • For immunohistochemistry: Test fixation compatibility

  • For ELISA: Establish standard curves and detection limits

Always document validation results and include appropriate controls in experiments.

What are optimal storage conditions for preserving antibody activity?

Based on general antibody handling practices :

• Temperature considerations:

  • Long-term storage: -20°C (most antibodies) or -80°C (some fragile antibodies)

  • Working solutions: 4°C for short periods (typically 1-2 weeks)

  • Avoid repeated freeze-thaw cycles by preparing small aliquots

• Buffer conditions:

  • Maintain recommended buffer composition (typically PBS with preservatives)

  • Some antibodies require specific stabilizers

  • Check for precipitation or aggregation before use

• Methodological approach to ensure antibody stability:

  • Implement a validation protocol for each new antibody lot

  • Include known positive controls in experiments to confirm activity

  • Document storage conditions and duration

  • Follow manufacturer's recommendations for specific antibodies

How can I use IL-17E/IL-25 antibody in ELISA detection assays?

Based on experimental data from search result :

• Recommended pairing:

  • Use IL-17E/IL-25 antibody (e.g., AF1258) as a detection antibody

  • Pair with Mouse Anti-Human IL-17E/IL-25 Monoclonal Antibody (e.g., MAB1258)

• Methodological considerations:

  • Optimal dilution range should be determined for each laboratory setup

  • Typical working concentration: 0.04-0.24 μg/mL in the presence of 5 ng/ml Recombinant Human IL-17E/IL-25

  • Ensure proper blocking to minimize background

  • Include standard curves using recombinant IL-17E/IL-25

• Sample preparation:

  • Can be used for detection in both serum and plasma samples

  • Sample dilution may be required depending on expected concentration

• Controls to include:

  • Positive control (known concentration of recombinant IL-17E/IL-25)

  • Negative control (buffer without target protein)

  • Isotype control antibody to assess non-specific binding

What experimental approaches can demonstrate anti-CD25 antibody efficacy in cancer immunotherapy?

Based on findings from recent research :

• In vitro assessment methods:

  • Flow cytometry to measure CD25+ Treg depletion efficiency

  • STAT5 phosphorylation assays to assess preservation of IL-2 signaling

  • ADCC and ADCP assays to evaluate depleting activity

• In vivo evaluation approaches:

  • Tumor challenge models to assess anti-tumor activity

  • Multiple dosing schedules to determine optimal treatment regimen

  • Combination studies with immune checkpoint blockade

  • Monitoring of effector T cell populations to ensure they are not depleted

• Key experimental findings:

  • Anti-CD25 antibodies optimized to deplete Tregs while preserving IL-2-STAT5 signaling on effector T cells demonstrate potent single-agent activity

  • These antibodies show synergy with immune checkpoint blockade in vivo

  • Multiple doses of non-IL-2 blocking anti-CD25 antibodies significantly increased complete responses compared to a single dose

How do radiolabeled CD25 antibodies compare with conventional therapies for lymphoma?

Based on clinical trial data from search result :

• Clinical efficacy:

  • CHT-25, a chimeric antibody to CD25 conjugated to iodine-131, showed clinical activity in patients with refractory CD25-positive lymphomas

  • At the maximum tolerated dose of 1,200 MBq/m², 6 of 9 patients responded (3 complete responses, 3 partial responses)

  • One of 6 patients receiving ≤740 MBq/m² had a complete response

• Safety profile:

  • Major side effect: Delayed myelotoxicity with platelet nadir at 38 days and neutrophil nadir at 53 days

  • Nonhematologic toxicity was mild

  • One patient treated with 2,960 MBq/m² developed prolonged grade 4 neutropenia and thrombocytopenia, resulting in fatal complications

• Pharmacokinetic considerations:

  • Single photon emission computer tomography imaging showed tumor-specific uptake and retention of ¹³¹I

  • No excessive retention in normal organs was observed

• Methodology for implementation:

  • Patient selection should focus on confirmed CD25 expression in tumor tissue

  • Careful monitoring of hematological parameters is essential

  • Phase II studies are warranted to determine efficacy and toxicity in broader clinical scenarios

What mechanisms distinguish IL-2-blocking from non-IL-2-blocking CD25 antibodies?

Based on mechanistic data from search result :

• Structural and functional differences:

  • IL-2-blocking antibodies: Bind to epitopes that interfere with IL-2/CD25 interaction

  • Non-IL-2-blocking antibodies: Bind to epitopes that allow IL-2 signaling while enabling Treg depletion

• Cellular effects:

  Antibody Type	Effect on Tregs	Effect on Effector T Cells	Anti-tumor Activity
  IL-2-blocking	Depletion + signaling blockade	Potential impairment of IL-2 signaling	Limited by effector T cell inhibition
  Non-IL-2-blocking	Efficient depletion	Preserved IL-2-STAT5 signaling	Enhanced, especially in combination therapy

• Optimization approaches:

  • Epitope mapping to identify non-blocking binding sites

  • Fc engineering (e.g., afucosylation) to enhance depleting activity

  • In vivo screening to select candidates with optimal Treg depletion/effector preservation balance

• Translational implications:

  • Non-IL-2-blocking anti-CD25 antibodies show potential for clinical development

  • RG6292, an anti-human CD25 antibody with these characteristics, demonstrates efficient Treg depletion with no overt immune-related toxicities in preclinical models

How does IL-17E/IL-25 antibody neutralization affect downstream inflammatory pathways?

Based on experimental data from search result :

• Signaling cascade:

  • IL-17E/IL-25 induces CXCL1/GRO alpha secretion in HT-29 human colon adenocarcinoma cell line in a dose-dependent manner

  • This process involves activation of downstream inflammatory pathways

  • Anti-IL-17E/IL-25 antibody neutralizes this activity in a concentration-dependent manner

• Quantitative parameters:

  • ND₅₀ (50% neutralization dose) for Goat Anti-Human IL-17E/IL-25 Antibody is typically 0.04-0.24 μg/mL in the presence of 5 ng/ml Recombinant Human IL-17E/IL-25

• Experimental methodology for pathway analysis:

  • Dose-response studies with varying concentrations of IL-17E/IL-25

  • Addition of neutralizing antibody at different concentrations

  • Measurement of CXCL1/GRO alpha secretion using appropriate detection methods (e.g., DuoSet ELISA)

  • Analysis of phosphorylation status of downstream signaling molecules

  • Gene expression profiling of inflammatory mediators

How are computational approaches improving antibody research and development?

Based on recent computational advancements described in search result :

• Language model applications in antibody research:

  • Training antibody-specific language models (LMs) on diverse sequence datasets

  • Addressing germline bias in antibody sequences that affects prediction accuracy

  • Using paired VH-VL data to improve modeling of antibody binding regions

• Challenges in computational antibody modeling:

  • LMs may "reproduce and even amplify biases in their training data"

  • Antibody germline bias presents as an imbalance problem in sequence prediction

  • Protein LMs have been shown to "struggle with mutations far from the wildtype"

• Methodological solutions:

  • Pre-processing training data or de-biasing with fine-tuning

  • Using techniques like up/down-sampling and focal loss to address imbalance

  • Recalibration for individual proteins with respect to background distribution

• Current research approaches:

  • Using clustered antibody sequences (95% identity) to create diverse training sets

  • Incorporating therapeutic antibody sequences from specialized databases

  • Developing models that can handle both unpaired and paired antibody chains

What opportunities exist in the 2025 antibody research landscape?

According to the 2025 Antibody Research Competition announcement :

• Emerging research priorities:

  • Antibody Engineering/Design

  • Antibody Therapeutics

  • Fc Effector Functions

  • Bispecific Antibodies

  • Antibody-Drug Conjugates

  • Adaptive Immune Receptor Repertoires

• Methodological innovations encouraged:

  • Traditional poster presentations

  • Creative formats like videos

  • Other unique presentation approaches

• Research development opportunities:

  • Early-career scientists (students and postdocs) are encouraged to contribute

  • Competition designed to recognize innovative research contributions

  • Support available through prizes and educational opportunities

What are best practices for antibody validation across different experimental systems?

Based on recommendations from the European Monoclonal Antibody Network :

• Standardization approaches:

  • Consistent use of unaltered original clone names for monoclonal antibodies

  • Reliable adoption of catalog and batch numbers for polyclonal antibodies

  • Making validation data (including images) available for independent review

• Technical validation hierarchy:

  • Specificity testing (highest priority)

  • Application-specific validation

  • Reproducibility across different experimental conditions

• Documentation requirements:

  • Clear identification of antibody source and identifiers

  • Detailed methods for validation experiments

  • Transparency about limitations of validation

• Methodological recommendations:

  • Even partially validated antibodies to new antigens have potential value to the research community

  • Mechanisms should be established for meaningful dialog between suppliers and users

  • Issues about reagents should be raised in a transparent fashion

How can researchers address batch-to-batch variability in antibody performance?

• Common sources of variability:

  • Production method differences (hybridoma vs. recombinant)

  • Post-translational modifications

  • Storage and handling conditions

  • "Even the same monoclonal antibody from different suppliers may exhibit variability in performance"

• Preventive strategies:

  • Purchase larger lots when possible to minimize switching between batches

  • Consider recombinant antibodies defined by their gene sequences for better standardization

  • Maintain detailed records of antibody performance by lot number

• Methodological approaches to minimize impact:

  • Establish validation protocols for each new batch

  • Include positive controls from previous batches in side-by-side comparisons

  • Normalize data to account for sensitivity differences between batches

  • Document batch numbers in publications and laboratory records

• Industry trends addressing variability:

  • Movement toward recombinant antibody production

  • Proposal that "polyclonal antibodies should be phased out and all monoclonal antibodies should be defined by their antibody gene sequences"

  • Development of reference standards for key research antibodies